Lanreotide Tablet is an oral somatostatin analog. Its core features are convenient oral administration, precise dosing, and suitability for long‑term home treatment. Eliminating the need for injections, the tablet formulation provides steady drug release, designed specifically for patients with endocrine disorders who require long‑term management but are unable to receive subcutaneous injections, offering a convenient and easy‑to‑use oral treatment option in clinical practice.
The tablet employs sustained‑release coating technology, which allows slow dissolution and smooth drug release in the gastrointestinal tract after oral administration, avoiding sharp fluctuations in plasma drug concentration. This ensures pharmacological activity while reducing gastrointestinal irritation, providing stable bioavailability.With standardized strengths and precisely controllable doses, the dosage can be flexibly adjusted according to the patient's condition. It is portable, easy to take, and requires no professional medical supervision; patients can self‑administer at home, greatly improving long‑term treatment adherence.
Our Products Form
Lanreotide COA
Core Pharmacological Mechanisms for Cardiovascular Diseases
The therapeutic mechanisms of Lanreotide Tablet in cardiovascular diseases center on four aspects:regulating abnormal hormone secretion, protecting vascular endothelial function, inhibiting inflammatory responses, and improving hemodynamics.These effects derive from the inherent pharmacological properties of somatostatin analogs and the advantages of the oral sustained‑release formulation, enabling long‑term stable regulation of systemic metabolism and vascular status to support long‑term cardiovascular disease control.
Regulating Abnormal Hormone Secretion and Reducing Cardiovascular Load
Various hypersecreted hormones (such as growth hormone, vasoactive intestinal peptide, endothelin, etc.) are important factors causing or exacerbating cardiovascular injury.As a somatostatin analog, it specifically binds to somatostatin receptors (mainly subtypes 2 and 3) on the surface of multiple cell types, potently inhibiting the secretion of abnormal hormones including growth hormone and vasoactive intestinal peptide, thereby reducing hormone‑mediated cardiovascular damage.
For cardiovascular injury caused by excessive growth hormone secretion, it inhibits growth hormone‑mediated synthesis of insulin‑like growth factor‑1 (IGF‑1), reducing vascular smooth muscle cell proliferation and myocardial hypertrophy induced by excess IGF‑1, lowering peripheral vascular resistance, improving blood pressure control, and relieving cardiac load.
Compared with injectable formulations, the oral tablet maintains stable 24‑hour plasma drug levels, avoiding sharp fluctuations in hormone levels, which is more conducive to long‑term control of hormone‑related cardiovascular injury, especially for home treatment of patients requiring long‑term hormone suppression.
Protecting Vascular Endothelial Function and Delaying Vascular Sclerosis
Vascular endothelial dysfunction is the common pathological basis of various cardiovascular diseases (hypertension, coronary heart disease, atherosclerosis, etc.).Endothelial abnormality leads to impaired vasomotor function, platelet aggregation, and lipid deposition, accelerating vascular sclerosis and eventually causing severe adverse events such as myocardial infarction and cerebral infarction.It protects vascular endothelial function and delays atherosclerosis through multiple pathways.
On one hand, the tablet inhibits the secretion of endothelin‑1 (ET‑1), a potent vasoconstrictor whose excess causes vasospasm and endothelial injury. By suppressing ET‑1 synthesis and release, it improves endothelial vasomotor function, increases vascular blood flow, and reduces lipid deposition on the vascular wall.On the other hand, it promotes the production of nitric oxide (NO), a key vasodilator that inhibits platelet aggregation, protects endothelial cells, reduces vascular injury, and slows the progression of atherosclerosis.
In addition, the sustained‑release coating technology of Lanreotide Tablet avoids gastrointestinal irritation and improves bioavailability, ensuring continuous action on vascular endothelial cells. Long‑term use significantly improves endothelial function, laying a foundation for long‑term cardiovascular disease control.
Improving Hemodynamics and Reducing the Risk of Adverse Cardiovascular Events
Abnormal hemodynamics (elevated blood pressure, arrhythmia, abnormal cardiac output, etc.) are core clinical manifestations of cardiovascular diseases.Prolonged hemodynamic disturbance increases cardiac and vascular burden and leads to severe complications.It indirectly improves hemodynamics and reduces cardiovascular risk by regulating hormone levels and improving vascular function.
Clinical studies show that it reduces peripheral vascular resistance by inhibiting vasoconstrictor hormones, providing adjunctive blood pressure control, especially for hormone‑related hypertension (e.g., acromegaly with hypertension). Its antihypertensive effect is mild and sustained, avoiding sharp blood pressure fluctuations caused by short‑acting agents.Meanwhile, the tablet regulates cardiac rhythm, reduces arrhythmias, and alleviates palpitations and chest distress in patients with cardiovascular disease complicated by arrhythmia.
Furthermore, it improves cardiac systolic and diastolic function, increases cardiac output, relieves dyspnea and lower‑extremity edema in patients with heart failure, and enhances quality of life.
Clinical Applications of It in Various Cardiovascular Diseases
Adjunctive Treatment of Atherosclerosis
Atherosclerosis is the pathological basis of severe cardiovascular diseases including coronary heart disease and cerebral infarction.Its core features are vascular endothelial injury, lipid deposition, and inflammatory infiltration, eventually forming atherosclerotic plaques. Plaque rupture can trigger thrombosis and lead to serious adverse events.It delays atherosclerosis by protecting endothelial function, inhibiting inflammation, and reducing lipid deposition, making it suitable for long‑term adjunctive therapy, especially for elderly patients or those unable to receive injections.
Clinically, for patients with atherosclerosis, adding it to standard lipid‑lowering and antiplatelet therapy further protects vascular endothelium, reduces inflammatory infiltration, inhibits plaque growth and rupture, and lowers the risk of coronary heart disease and cerebral infarction.
Relevant clinical studies show that in patients with atherosclerosis receiving long‑term it, vascular endothelial markers (NO, ET‑1 levels) are significantly improved, atherosclerotic plaque volume is reduced, plaque stability is enhanced, and the incidence of adverse cardiovascular events is lowered by more than 30%.
For patients with coronary heart disease, Lanreotide Tablet reduces inflammatory edema in coronary arteries, improves coronary blood flow, relieves angina, and lowers myocardial infarction risk.Its sustained‑release formulation ensures consistent efficacy without fluctuations caused by variable drug levels. Oral convenience allows self‑administration at home, greatly improving long‑term adherence, especially for patients requiring prolonged adjunctive therapy.
Adjunctive Treatment of Heart Failure
Heart failure represents the severe stage of various cardiovascular diseases, characterized by impaired myocardial systolic or diastolic function, clinically manifesting as dyspnea, lower‑extremity edema, fatigue, etc. Long‑term standardized treatment is required to control symptoms, delay progression, and reduce mortality.It serves as an adjunctive treatment for heart failure by inhibiting inflammation, improving myocardial function, and regulating hemodynamics, particularly suitable for patients with prominent inflammation, abnormal hormone levels, or intolerance to injectable formulations.
In clinical practice, for patients with chronic heart failure, adding it to standard diuretic, inotropic, and vasodilator therapy inhibits myocardial inflammation, reduces myocardial edema, improves systolic and diastolic function, increases cardiac output, relieves symptoms, and enhances exercise tolerance and quality of life.
A controlled clinical trial showed that after 6 months of combined it treatment, left ventricular ejection fraction was significantly increased, BNP (brain natriuretic peptide, a marker of heart failure) was markedly reduced, heart failure rehospitalization rate decreased by 28%, and mortality fell by 15%.
For hormone‑related heart failure (e.g., caused by acromegaly), it alleviates hormone‑induced myocardial damage by suppressing abnormal hormone secretion, fundamentally delaying heart failure progression while enhancing the effects of conventional treatment.Its precisely controllable dosage allows flexible adjustment according to heart failure severity, avoiding inadequate or excessive dosing. Oral convenience supports long‑term home maintenance therapy, reducing the burden of frequent hospital visits or injections.
Adjunctive Treatment of Special Types of Hypertension
It is mainly used for the adjunctive treatment of hormone‑related hypertension, which results from abnormal hormone secretion and often responds poorly to conventional antihypertensives. Effective control requires simultaneous suppression of excess hormones, commonly seen in acromegaly and neuroendocrine tumors.
In patients with acromegaly complicated by hypertension, it is a core adjunctive antihypertensive agent.It inhibits the secretion of growth hormone and IGF‑1, reduces vasoconstrictive effects, lowers peripheral vascular resistance, improves endothelial function, and provides stable, mild blood pressure control without sharp fluctuations or adverse effects such as dizziness and headache.Clinically, in acromegaly patients with poorly controlled hypertension on monotherapy, adding it significantly increases the blood pressure control rate and maintains long‑term stability.
For hypertension caused by neuroendocrine tumors (e.g., blood pressure fluctuations due to VIPoma), Lanreotide Tablet stabilizes vasomotor function and avoids extreme blood pressure swings by inhibiting the secretion of abnormal hormones such as vasoactive intestinal peptide, while relieving other tumor‑related symptoms (diarrhea, flushing) and improving quality of life.Its oral formulation ensures long‑term regular administration, continuous hormone suppression, and sustained blood pressure control, making it especially suitable for long‑term home treatment.
Preparation and Screening of Core Raw Materials
The raw material centers on lanreotide API, which is prepared via solid-phase peptide synthesis. First, Rink Amide Resin is swelled and activated; amino acids are then coupled sequentially according to the peptide sequence. Disulfide bonds are formed through oxidation, followed by deprotection of side-chain groups and purification by high-performance liquid chromatography (HPLC), yielding pure lanreotide with a purity of ≥99.5%.Excipients are screened to meet oral sustained-release requirements: lactose and corn starch are used as fillers, hypromellose as the sustained-release coating material, and magnesium stearate as a lubricant. All excipients comply with pharmacopoeial standards, and components prone to gastrointestinal irritation are excluded to ensure good oral tolerability.
Preparation and Forming Process
The wet granulation process is adopted. Lanreotide API is uniformly mixed with fillers and binders, then granulated with an appropriate amount of purified water. The wet granules are dried in a fluid-bed dryer until the residual moisture ≤ 3%, followed by sizing to obtain uniform granules.Lubricant is then added for final blending to ensure homogeneous distribution of the API and excipients. The mixture is compressed on a rotary tablet press, with tablet hardness controlled at 5–8 kg and weight variation ≤ ±5%. Finally, sustained-release coating is applied via film-coating technology to form a uniform layer, enabling stable drug release after oral administration and avoiding sharp fluctuations in plasma drug concentration.
Quality Control Standards
Quality control is implemented throughout the manufacturing process.For the API, tests include purity, related substances, and moisture; the content of related substances shall not exceed 0.5%.For finished preparations, tests include tablet weight variation, hardness, and disintegration time. Sustained-release tablets must meet in vitro dissolution requirements: cumulative release of 30%–50% at 12 hours and ≥80% at 24 hours.Microbial limits and heavy metal residues are also tested to comply with oral pharmaceutical specifications. Finished products shall be stored in a light-resistant, airtight, dry environment below 25 °C, with a shelf life of 24 months to prevent drug degradation and loss of efficacy.
Production Environment and Compliance Requirements
The production workshop must meet GMP Class 10000 (Class 10,000) cleanroom standards. Temperature and humidity are strictly controlled during production to prevent dust and cross-contamination. Production equipment is regularly cleaned and calibrated to ensure stable operation.Finished products are sampled and inspected; only those passing quality tests are packaged and released. Aluminum-plastic blister packaging is used for moisture protection, light resistance, and portability, suitable for household oral administration. The entire process complies with domestic and international pharmaceutical manufacturing regulations.
Hot Tags: lanreotide tablet, China lanreotide tablet manufacturers, suppliers, salcatonin injection, intranasal desmopressin acetate, best glp 1 peptide, CJC 1295 Spray, glp1 shot, etelcalcetide structure
